Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers. (Q37199205)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

0 references

ventricular dysfunction

1 reference

based on heuristic

inferred from title

left ventricular dysfunction

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Jennifer E Stark

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

920-931

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18576907%20AND%20SRC:MED&resulttype=core&format=json

Rethinking the renin-angiotensin system and its role in cardiovascular regulation.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Neurohumoral blockade in CHF management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Chronic mineralocorticoid excess and cardiovascular remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

The renin-angiotensin-aldosterone system: a specific target for hypertension management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Changes in left ventricular anatomy and function in hypertension and primary aldosteronism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.7.920